RCBTB1

Across TCGA pan-cancer cohorts, RCBTB1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RCBTB1 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RCBTB1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RCBTB1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where RCBTB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.241	0.807	.007	32	view →
PDAC	OS	Median	II,III,IV	0.719	0.360	.008	9	view →
HNSC	DFS	Tertile	III,IV	0.928	0.528	.009	7	view →
LSCC	DFS	Median	III,IV	0.611	0.908	.039	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RCBTB1–LUAD (DFS)

Open the LUAD breakdown →